Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

10-Week therapy aims to curb impulsive behaviors in young BPD patients

NCT ID NCT05913544

Symptom relief Sponsor: Centre Hospitalier Universitaire de Nīmes Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a 10-week therapy program called SINTYA for young adults aged 16-25 with borderline personality disorder (BPD). The program combines group and individual sessions to reduce impulsivity and related symptoms like emotional distress, self-harm, and suicide risk. Researchers aim to see if this short, tailored approach works better than standard care for this age group.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 74 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2023

Expected to finish

Sep 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

16 to 25 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of BPD according to DSM-5 criteria and BPQ-80 scale. * High BPD severity level: ZAN-BPD (score ≥ 18/36). * Understand, write and read French. * Be able to understand the nature, purpose and methodology of the study and agree to cooperate during evaluations. * Have signed the informed consent. * For minor patients, have signed the parental consent by at least one holder of parental authority. Exclusion Criteria: * Refusal to participate. * Existence of a neurological pathology or cerebral sequelae of organic origin which could affect neurocognitive performance. * Intelligence quotient \< 70. * Lifetime diagnosis of schizoaffective disorder or schizophrenia (MINI-7). * Previous or current participation in specific psychotherapy for BPD. * Subject deprived of liberty (by judicial or administrative decision) and/or protected by law. * Inclusion in another study including psychotherapy for the duration of the study. * Inclusion in a drug RIPH1 study or in a REC study (European regulation of clinical trials) for the entire duration of the study. * Subject in period of exclusion from another research protocol.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Borderline personality disorder are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

borderline personality disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Borderline personality disorder

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CHU de Nîmes

    RECRUITING

    Nîmes, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.